DBV Technologies saw a sharp revenue decline but slightly reduced its net loss year-over-year. Cash usage remained high, driven by clinical and regulatory activities. A major financing round closed after quarter-end is expected to fund operations into mid-2026.

DBV Technologies reported its Q3 2024 financial results, revealing a cash balance of $46.4 million. The company's operating income was $1.1 million. The company experienced a net loss of $30.4 million, with a basic/diluted net loss per share of $(0.32).

DBV Technologies reported financial results for the second quarter of 2024, with a cash balance of $66.2 million. Enrollment for the VITESSE Phase 3 pivotal study is on track, and the company submitted a labeling proposal to the FDA for the COMFORT Toddlers study.

DBV Technologies reported a net loss of $27.3 million for Q1 2024, with cash and cash equivalents at $101.5 million. The company is progressing with its VITESSE Phase 3 clinical trial and appointed a new Chief Regulatory Officer.

DBV Technologies reported cash and cash equivalents of $141.4 million as of December 31, 2023. The company experienced a net loss of $72.7 million for the year ended December 31, 2023. They are focused on completing enrollment in VITESSE, their Phase 3 efficacy and safety trial in children.

DBV Technologies announced the receipt of written feedback from the FDA regarding the COMFORT supplemental safety studies and reported financial results for Q3 2023. The company's cash and cash equivalents amounted to $149.1 million as of September 30, 2023.

DBV Technologies announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT Toddlers and COMFORT Children supplemental safety studies. The company closed Q2 2023 with a cash balance of $174 million.

DBV Technologies reported a net loss of $20.5 million for Q1 2023, with cash and cash equivalents of $192.3 million. The company's operating expenses increased due to the initiation of the VITESSE trial.

DBV Technologies reported full year 2022 financial results, highlighting the completion of the EVOLVE study and a cash and cash equivalents balance of $209.2 million as of December 31, 2022.

DBV Technologies reported its Q3 2022 financial results, highlighting a cash balance of $212.7 million and a decrease in operating expenses. The company is actively engaging with the FDA regarding the partial clinical hold on the VITESSE Phase 3 clinical study.

DBV Technologies reported a net loss of $23.0 million for the second quarter of 2022, compared to a net loss of $30.7 million for the same period in 2021. The company closed the quarter with $248.0 million in cash and cash equivalents, benefiting from ATM and PIPE offerings. DBV continues its focus on budget discipline, with cash used in operating activities decreasing significantly compared to the previous year.

DBV Technologies reported a net loss of $16.7 million for the first quarter of 2022, with cash and cash equivalents totaling $74.1 million. The FDA granted a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol. The company expects its current cash and cash equivalents to support operations into Q1 2023.

DBV Technologies reported full year 2021 financial results. The company's cash and cash equivalents were $77.3 million. Net loss was $(97.8) million under U.S. GAAP and $(98.1) million under IFRS.

DBV Technologies reported financial results for the third quarter of 2021. Cash and cash equivalents were $98.2 million as of September 30, 2021. Net loss was $(24.0) million, or $(0.44) per share.

DBV Technologies reported a net loss of $30.7 million for the second quarter of 2021. The company continues to advance Viaskin Peanut's regulatory dossier and expects its current cash and cash equivalents to support operations until the second half of 2022.